|
|
|
|
Changes in Cardiovascular Risk Estimation and Fasting Lipids in Virologically Suppressed Patients
Randomized to Switch to Tenofovir Alafenamide versus Continuing Abacavir
|
|
|
Reported by Jules Levin
22nd International AIDS Conference (AIDS 2018), Amsterdam, Netherlands, 23-27 July 2018
Alan Winston,1 David Wohl,2 Hans Jurgen Stellbrink,3 Luis Lopez-Cortes,4 Paddy Mallon,5 Paul Sax,6 Indira Brar,7 Ya-Pei Liu,8 Lijie Zhong,8 Sean E. Collins,8 Hal Martin,8 Devi SenGupta,8 Erin Quirk,8 Moupali Das8
1Imperial College, London, UK; 2Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA; 3ICH Study Center, Hamburg, Germany; 4Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain;
5School of Medicine, University College Dublin, Ireland; 6Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA; 7Henry Ford Hospital, Detroit, Michigan, USA; 8Gilead Sciences, Inc., Foster City, California, USA
References
1. Islam FM, et al. HIV Med 2012;13:453-68;
2. D:A:D Study Group, Smith C. AIDS 2010;24:1537-48;
3. Hadigan C, et al. JAMA Cardiol 2017;2:123-4;
4. D:A:D Study Group. N
Engl J Med 2003;349:1993-2003;
5. Elion RA, et al. JAIDS 2018;78:62-72;
6. Friis-Møller N, et al. Eur J Prev Cardiol 2016;23:214-23;
7. Goff DC, et al. Circulation
2014;129(Suppl 2):S49-73;
8. Feinstein MJ, et al. JAMA Cardiology 2017;2:155-62. European AIDS Clinical Society (EACS) Guidelines Version 9.0. October 2017.
http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html . Accessed 6 June 2018;
9. US Preventive Services Task Force. JAMA 2016;316:1997-2007.
|
|
|
|
|
|
|